NEW YORK (GenomeWeb) – Myriad Genetics has entered into an accelerated share repurchase program with Bank of America to buy back $50 million of its common stock.

Under the terms of the agreement, Myriad will repurchase shares of its common stock discounted to the volume-weighted average share price on Nov. 16 equaling $50 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.